ACRISEU

This brand name is authorized in Finland.

Active ingredients

The drug ACRISEU contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII A20F9XAI7W - ACRIVASTINE
 

Acrivastine, a structural analog of triprolidine hydrochloride, exhibits H1-antihistaminic activity in isolated tissues, animals, and humans, and has sedative effects in humans. The propionic acid derivative of acrivastine is a metabolite in several animal species (as well as in man) and also exhibits H1-antihistaminic activity.
 
Read more about Acrivastine
2
UNII 6V9V2RYJ8N - PSEUDOEPHEDRINE HYDROCHLORIDE
 

Pseudoephedrine is a sympathomimetic agent with direct and indirect effects on adrenergic receptors. It has alpha and beta adrenergic activity and some stimulant effect on the central nervous system. The sympathomimetic effect of pseudoephedrine produces vasoconstriction which in turn relieves nasal congestion.
 
Read more about Pseudoephedrine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
R01BA52 Pseudoephedrine, combinations R Respiratory system → R01 Nasal preparations → R01B Nasal decongestants for systemic use → R01BA Sympathomimetics
Discover more medicines within R01BA52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
FI Lääkealan turvallisuus- ja kehittämiskeskus 114982, 131667, 449502

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈